<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>856</ReferenceId>
        <DateLastUpdated>2018-10-16-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10694575</PubmedId>
            <Abstract>Mice that lack CD4(+) T cells remain clinically normal for more than 60 days after respiratory challenge with the murine gamma-herpesvirus 68 (gammaHV-68), then develop symptoms of a progressive wasting disease. The gammaHV-68-specific CD8(+) T cells that persist in these I-A(b-/-) mice are unable to prevent continued, but relatively low level, virus replication. Postexposure challenge with recombinant vaccinia viruses expressing gammaHV-68 lytic cycle epitopes massively increased the magnitude of the gammaHV-68-specific CD8(+) population detectable by staining with tetrameric complexes of MHC class I glycoprotein + peptide, or by interferon-gamma production subsequent to in vitro restimulation with peptide. The boosting effect was comparable for gammaHV-68-infected I-A(b-/-) and I-A(b+/+) mice within 7 days of challenge, and took more than 110 days to return to prevaccination levels in the I-A(b+/+) controls. Although the life-span of the I-A(b-/-) mice was significantly increased, there was no effect on long-term survival. A further boost with a recombinant influenza A virus failed to improve the situation. Onset of weight loss was associated with a decline in gammaHV-68-specific CD8(+) T cell numbers, though it is not clear whether this was a cause or an effect of the underlying pathology. Even very high levels of virus-specific CD8(+) T cells thus provide only transient protection against the uniformly lethal consequences of gammaHV-68 infection under conditions of CD4(+) T cell deficiency.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>2725-30</ArticlePages>
            <ArticleTitle>Postexposure vaccination massively increases the prevalence of gamma-herpesvirus-specific CD8+ T cells but confers minimal survival advantage on CD4-deficient mice.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Belz</LastName>
                    <ForeName>G T</ForeName>
                </Author>
                <Author>
                    <LastName>Stevenson</LastName>
                    <ForeName>P G</ForeName>
                </Author>
                <Author>
                    <LastName>Castrucci</LastName>
                    <ForeName>M R</ForeName>
                </Author>
                <Author>
                    <LastName>Altman</LastName>
                    <ForeName>J D</ForeName>
                </Author>
                <Author>
                    <LastName>Doherty</LastName>
                    <ForeName>P C</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliations>
            <ArticleChemicalList>Viral Vaccines</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; CD4-Positive T-Lymphocytes(immunology; virology); CD8-Positive T-Lymphocytes(immunology; virology); Cells, Cultured; Female; Flow Cytometry; Gammaherpesvirinae(immunology); Lung(immunology; virology); Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Peritoneum(immunology; virology); Spleen(immunology; virology); Time Factors; Vaccinia virus(metabolism); Viral Vaccines(therapeutic use)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>97</Volume>
                <Issue>6</Issue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <Issn>0027-8424</Issn>
                <MedlineTa>Proc Natl Acad Sci U S A</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>p56</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AGPHNDMEI</LinearSequence>
                        <StartingPosition>487</StartingPosition>
                        <EndingPosition>495</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB66385.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000537</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 2725</LocationOfData>
                <EpitopeId>1635</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1 and figure 2</LocationOfData>
                        <TCellId>9362</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000537</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>One immunization with 600 pfu one month before i.p. challenge with 3x10&lt;sup&gt;7&lt;/sup&gt; pfu of recombinant vaccinia virus expressing epitope.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p56</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGPHNDMEI</LinearSequence>
                                        <StartingPosition>487</StartingPosition>
                                        <EndingPosition>495</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66385.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000537</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Source species infected mice were challenged with recombinant vaccinia virus expressing the epitope. Spleen CD8+ cells specific for epitope were significantly enhanced, as seen in peritoneal lavage. This effect was long lasting (&gt;70d). IFN-g expression measurement yielded similar results.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>9361</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000223</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000537</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>One immunization with 600 pfu one month before i.p. challenge with 3x10&lt;sup&gt;7&lt;/sup&gt; pfu of recombinant vaccinia virus expressing epitope.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p56</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGPHNDMEI</LinearSequence>
                                        <StartingPosition>487</StartingPosition>
                                        <EndingPosition>495</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66385.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000537</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Source species infected MHC-II null mice were challenged with recombinant vaccinia virus expressing the epitope. Spleen CD8+ cells specific for the epitope were significantly enhanced. This effect was long lasting (&gt;60d) and was similar to the response seen in wild type mice. IFN-g expression measurement yielded similar results. Extra boosting with Influenza expressing epitope did not induce a higher level of CD8+ specific cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>9363</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000223</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000537</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>One immunization with 600 pfu one month before i.p. challenge with 3x10&lt;sup&gt;7&lt;/sup&gt; pfu of recombinant vaccinia virus expressing epitope.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p56</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AGPHNDMEI</LinearSequence>
                                        <StartingPosition>487</StartingPosition>
                                        <EndingPosition>495</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66385.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000537</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>127</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Source species infected MHC-II null mice were challenged with recombinant vaccinia virus expressing the epitope. Survival was increased in comparison to control challenged mice, but wasting finally developed, due to the persistent lytic phase infection observed in these mice. Virus isolated from these mice were not escape mutants, suggesting that the deficit in clearance was due to the lack of CD4+ cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>p79</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>NTSINFVKI</LinearSequence>
                        <StartingPosition>523</StartingPosition>
                        <EndingPosition>531</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAB66451.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10000537</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 2725</LocationOfData>
                <EpitopeId>46263</EpitopeId>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>9364</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000223</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000537</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>One immunization with 600 pfu one month before i.p. challenge with 3x10&lt;sup&gt;7&lt;/sup&gt; pfu of recombinant vaccinia virus expressing epitope.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p79</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NTSINFVKI</LinearSequence>
                                        <StartingPosition>523</StartingPosition>
                                        <EndingPosition>531</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000537</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Source species infected MHC-II null mice were challenged with recombinant vaccinia virus expressing the epitope. Spleen CD8+ cells specific for epitope were significantly enhanced. This effect is long lasting (&gt;60d) and is similar to the response seen in wild type mice. IFN-g expression measurement yields similar results. Extra boosting with Influenza expressing epitope did not induce a higher level of CD8+ specific cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>9366</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000223</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo to prevent or reduce disease</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000537</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>One immunization with 600 pfu one month before i.p. challenge with 3x10&lt;sup&gt;7&lt;/sup&gt; pfu of recombinant vaccinia virus expressing epitope.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p79</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NTSINFVKI</LinearSequence>
                                        <StartingPosition>523</StartingPosition>
                                        <EndingPosition>531</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000537</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>127</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Source species infected MHC-II null mice were challenged with recombinant vaccinia virus expressing the epitope. Survival was not increased in comparison to control challenged mice, and wasting finally developed, due to the persistent lytic phase infection observed in these mice. Virus isolated from these mice were not escape mutants, suggesting that the deficit in clearance was due to the lack of CD4+ cells.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1 and figure 2</LocationOfData>
                        <TCellId>9365</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-12 wk.</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>10000537</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intranasal</Route>
                                <DoseSchedule>One immunization with 600 pfu one month before i.p. challenge with 3x10&lt;sup&gt;7&lt;/sup&gt; pfu of recombinant vaccinia virus expressing epitope.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>p79</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>NTSINFVKI</LinearSequence>
                                        <StartingPosition>523</StartingPosition>
                                        <EndingPosition>531</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAB66451.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10000537</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Source species infected mice were challenged with recombinant vaccinia virus expressing the epitope. Spleen CD8+ cells specific for epitope were significantly enhanced, as seen in peritoneal lavage. This effect was long lasting (&gt;70d). IFN-g expression measurement yielded similar results.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

